Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Keros Therapeutics, Inc. - common stock (NQ:KROS)

16.55 +0.38 (+2.35%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 332,669
Open 16.17
Bid (Size) 15.40 (300)
Ask (Size) 19.95 (100)
Prev. Close 16.17
Today's Range 16.06 - 16.68
52wk Range 9.120 - 22.55
Shares Outstanding 23,337,862
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Keros Therapeutics Inc (NASDAQ:KROS) Emerges as a High-Growth Momentum Breakout Candidate ↗
Keros Therapeutics exemplifies a high-growth momentum strategy, combining explosive revenue growth, perfect technical ratings, and a defined breakout setup for potential entry. 
Via Chartmill
News headline image
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst ↗
BofA's Zemansky downgraded Keros to Neutral, citing limited near-term upside, cautious sentiment, and unresolved investor concerns. 
Via Benzinga

Performance

YTD
-10.7%
-10.7%
1 Month
-10.2%
-10.2%
3 Month
-1.8%
-1.8%
6 Month
+16.3%
+16.3%
1 Year
+56.7%
+56.7%

More News

Read More
News headline image
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% ↗
Via Benzinga
News headline image
Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price ↗
Via Benzinga
News headline image
Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan ↗
Via Benzinga
News headline image
Analyst Expectations For Keros Therapeutics's Future ↗
Via Benzinga
News headline image
Deep Dive Into Keros Therapeutics Stock: Analyst Perspectives (11 Ratings) ↗
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Keros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s Overjoyed ↗
Via Stocktwits
News headline image
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump ↗
Via Benzinga
News headline image
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday ↗
Via Benzinga
News headline image
Where Keros Therapeutics Stands With Analysts ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Forecasting The Future: 7 Analyst Projections For Keros Therapeutics ↗
Via Benzinga
News headline image
KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. on Behalf of Keros Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Keros Therapeutics, Inc. (KROS)
From Kirby McInerney LLP
Via Business Wire
News headline image
Crude Oil Rises Sharply; JPMorgan Chase Earnings Top Views ↗
Via Benzinga
News headline image
Nasdaq Surges Over 2%; Goldman Sachs Posts Upbeat Q4 Results ↗
Via Benzinga
News headline image
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes ↗
Via Stocktwits
News headline image
Keros Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - KROS
Via ACCESSWIRE
News headline image
Shareholders that lost money on Keros Therapeutics, Inc.(KROS) should contact Levi & Korsinsky about Securities Fraud Investigation - KROS
Via ACCESSWIRE
News headline image
Levi & Korsinsky Announces an Investigation on Behalf of Keros Therapeutics, Inc. (KROS) Shareholders Who May Have Been Affected by Fraud
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher ↗
Via Benzinga
Topics Stocks
News headline image
Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook ↗
Via Benzinga

Frequently Asked Questions

Is Keros Therapeutics, Inc. - common stock publicly traded?
Yes, Keros Therapeutics, Inc. - common stock is publicly traded.
What exchange does Keros Therapeutics, Inc. - common stock trade on?
Keros Therapeutics, Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Keros Therapeutics, Inc. - common stock?
The ticker symbol for Keros Therapeutics, Inc. - common stock is KROS on the Nasdaq Stock Market
What is the current price of Keros Therapeutics, Inc. - common stock?
The current price of Keros Therapeutics, Inc. - common stock is 16.55
When was Keros Therapeutics, Inc. - common stock last traded?
The last trade of Keros Therapeutics, Inc. - common stock was at 02/19/26 04:00 PM ET
What is the market capitalization of Keros Therapeutics, Inc. - common stock?
The market capitalization of Keros Therapeutics, Inc. - common stock is 386.24M
How many shares of Keros Therapeutics, Inc. - common stock are outstanding?
Keros Therapeutics, Inc. - common stock has 386M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.